Mirum Pharmaceuticals’ experimental monoclonal antibody brelovitug met the main goal of the Phase 3 AZURE-1 trial in chronic hepatitis delta virus. After 24 weeks, 56% of patients receiving 300 milligrams and 45% receiving 900 milligrams achieved reduced hepatitis D virus levels and normal liver enzyme readings, compared with 0% in the delayed-treatment group. Mirum said brelovitug was well tolerated, with a safety profile consistent with earlier data, and plans to submit a marketing application to the U.S. Food and Drug Administration in the first half of 2027. H.C. Wainwright raised its price target for Mirum from $140 to $195, citing the trial result and FDA approval of Atebrioz™ as positive developments.